公开(公告)号：US20150099720A1

公开(公告)日：2015-04-09

申请号：US14519053

申请日：2014-10-20

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Lin Zhi ,  Robert I. Higuchi ,  E. Adam Kallel ,  Cornelis Arjan Van Oeveren ,  Jyun-Hung Chen ,  Daniel A. Ruppar ,  Bijan Pedram ,  Thomas Lot Stevens Lau ,  Todd A. Miller

IPC: C07C211/52 ,  C07F7/18 ,  C07D207/27 ,  C07C205/55 ,  C07D209/12 ,  C07D211/60 ,  C07D211/22 ,  C07C255/58 ,  C07D207/08

CPC classification number: C07C211/52 ,  C07C205/55 ,  C07C255/58 ,  C07C2601/08 ,  C07D207/08 ,  C07D207/09 ,  C07D207/12 ,  C07D207/16 ,  C07D207/26 ,  C07D207/27 ,  C07D207/46 ,  C07D209/04 ,  C07D209/08 ,  C07D209/12 ,  C07D211/22 ,  C07D211/56 ,  C07D211/60 ,  C07D215/04 ,  C07D215/18 ,  C07D265/36 ,  C07D295/073 ,  C07F7/1804 ,  G01N2333/723

Abstract: Provided herein are compounds having a structure selected from among Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V) and Formula (VI) that are androgen receptor modulators and/or androgen receptor binding agents. Also disclosed are methods of making and using such compounds, including, but not limited to, using such compounds for treating various conditions.

Abstract translation: 本文提供具有选自式（I），式（II），式（III），式（IV），式（V）和式（VI））的结构的化合物，其是雄激素受体调节剂和/或雄激素受体结合 代理商 还公开了制备和使用这些化合物的方法，包括但不限于使用这些化合物来处理各种条件。

公开(公告)号：US20140005186A1

公开(公告)日：2014-01-02

申请号：US13974937

申请日：2013-08-23

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Lin Zhi ,  Robert I. Higuchi ,  E. Adam Kallel ,  Cornelis Arjan Van Oeveren ,  Jyun-Hung Chen ,  Daniel A. Ruppar ,  Bijan Pedram ,  Thomas Lot Stevens Lau ,  Todd A. Miller

IPC: C07D265/36 ,  C07D207/46 ,  C07D209/04 ,  C07D215/04 ,  C07D211/56

CPC classification number: C07C211/52 ,  C07C205/55 ,  C07C255/58 ,  C07C2601/08 ,  C07D207/08 ,  C07D207/09 ,  C07D207/12 ,  C07D207/16 ,  C07D207/26 ,  C07D207/27 ,  C07D207/46 ,  C07D209/04 ,  C07D209/08 ,  C07D209/12 ,  C07D211/22 ,  C07D211/56 ,  C07D211/60 ,  C07D215/04 ,  C07D215/18 ,  C07D265/36 ,  C07D295/073 ,  C07F7/1804 ,  G01N2333/723

Abstract: Provided herein are compounds having a structure selected from among Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V) and Formula (VI) that are androgen receptor modulators and/or androgen receptor binding agents. Also disclosed are methods of making and using such compounds, including, but not limited to, using such compounds for treating various conditions.

Abstract translation: 本文提供具有选自式（I），式（II），式（III），式（IV），式（V）和式（VI））的结构的化合物，其是雄激素受体调节剂和/或雄激素受体结合 代理商 还公开了制备和使用这些化合物的方法，包括但不限于使用这些化合物来处理各种条件。

公开(公告)号：US11858938B2

公开(公告)日：2024-01-02

申请号：US17071273

申请日：2020-10-15

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Lin Zhi

IPC: C07D487/04

CPC classification number: C07D487/04

Abstract: Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using imidazole-fused heterocycle amines. Some of the disclosed embodiments include imidazo-fused heterocycle compounds useful to treat leukemia and other hematopoietic disorders.

公开(公告)号：US11773110B2

公开(公告)日：2023-10-03

申请号：US17513093

申请日：2021-10-28

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Koc-Kan Ho ,  David Diller ,  Jeffrey J. Letourneau ,  Brian F. McGuinness ,  Andrew G. Cole ,  David Rosen ,  Cornelis A. van Oeveren ,  Jason C. Pickens ,  Lin Zhi ,  Yixing Shen ,  Bijan Pedram

IPC: C07D235/02 ,  C07D269/02 ,  C07D277/42 ,  C07D277/60 ,  C07D513/04 ,  A61K31/407 ,  A61K31/4168 ,  A61K31/4353 ,  A61P29/00 ,  A61P37/00 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04

CPC classification number: C07D513/04 ,  A61K31/407 ,  A61K31/4168 ,  A61K31/4353 ,  A61P29/00 ,  A61P37/00 ,  C07D235/02 ,  C07D269/02 ,  C07D277/42 ,  C07D277/60 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04

Abstract: Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using heterocycle amines. Some of the disclosed embodiments include heterocycle amines useful to treat inflammatory disorders.

公开(公告)号：US10604533B2

公开(公告)日：2020-03-31

申请号：US16015925

申请日：2018-06-22

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Koc-Kan Ho ,  David Diller ,  Jeffrey J. Letourneau ,  Brian F. McGuinness ,  Andrew G. Cole ,  David Rosen ,  Cornelis A. van Oeveren ,  Jason C. Pickens ,  Lin Zhi ,  Yixing Shen ,  Bijan Pedram

IPC: C07D213/02 ,  C07D401/04 ,  C07D471/04 ,  C07D513/04 ,  A61K31/407 ,  A61K31/4168 ,  A61K31/4353 ,  C07D235/02 ,  C07D269/02 ,  C07D277/42 ,  C07D277/60 ,  A61P29/00 ,  A61P37/00 ,  C07D417/12 ,  C07D417/14

Abstract: Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using heterocycle amines. Some of the disclosed embodiments include heterocycle amines useful to treat inflammatory disorders.

公开(公告)号：US10420748B2

公开(公告)日：2019-09-24

申请号：US15908504

申请日：2018-02-28

Applicant: LIGAND PHARMACEUTICALS INCORPORATED

Inventor： Keith B. Marschke ,  Lin Zhi

IPC: A61K31/4045 ,  A61K31/4152 ,  A61K45/06 ,  A61K31/41 ,  A61K31/4155 ,  A61K31/454 ,  A61N5/10 ,  G01N33/50 ,  A61K31/40 ,  A61K31/4015

Abstract: Some embodiments include methods for treating, preventing, reversing, halting, or slowing the progression of cancer, comprising administering to a subject in need thereof an effective amount of one or more chemotherapeutic agents, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, wherein at least one of the chemotherapeutic agents is a cytotoxic granulocyte colony-stimulating factor receptor (GCFR) modulator. Methods are also disclosed for treating, preventing, reversing, halting, or slowing the progression of a hematopoietic disorder, comprising administered a therapeutically effective cytotoxic amount of a GCFR modulator to a subject in need thereof.

公开(公告)号：US09676809B2

公开(公告)日：2017-06-13

申请号：US15034757

申请日：2014-11-19

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Lin Zhi

IPC: C07H19/10 ,  C07H19/11

CPC classification number: C07H19/10 ,  C07H19/11

Abstract: Some embodiments of the present invention include nucleoside 5′-monophosphate derivative compounds, their preparation and their uses. In some embodiments, such compounds are useful to treat hepatitis C viral infections.

公开(公告)号：US09266874B2

公开(公告)日：2016-02-23

申请号：US14137318

申请日：2013-12-20

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Koc-Kan Ho ,  David Diller ,  Jeffrey J. Letourneau ,  Brian F. McGuinness ,  Andrew G. Cole ,  David Rosen ,  Cornelis A. van Oeveren ,  Jason C. Pickens ,  Lin Zhi ,  Yixing Shen ,  Bijan Pedram

IPC: C07D417/14 ,  C07D417/12 ,  A61K31/407 ,  A61K31/4168 ,  A61K31/4353 ,  C07D235/02 ,  C07D269/02 ,  C07D277/42 ,  C07D277/60 ,  C07D471/04 ,  C07D513/04

CPC classification number: C07D513/04 ,  A61K31/407 ,  A61K31/4168 ,  A61K31/4353 ,  A61P29/00 ,  A61P37/00 ,  C07D235/02 ,  C07D269/02 ,  C07D277/42 ,  C07D277/60 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04

Abstract: Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using heterocycle amines. Some of the disclosed embodiments include heterocycle amines useful to treat inflammatory disorders.

Abstract translation: 公开了化学和医学领域中的化合物和方法。 一些所公开的实施方案包括使用杂环胺的化合物，组合物和方法。 一些所公开的实施方案包括可用于治疗炎症性疾病的杂环胺。

公开(公告)号：US20140350065A1

公开(公告)日：2014-11-27

申请号：US14263237

申请日：2014-04-28

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Lin Zhi

IPC: C07D207/16

CPC classification number: C07D207/09 ,  A61K31/401 ,  A61K31/402 ,  A61K31/5383 ,  A61K45/06 ,  C07D207/08 ,  C07D207/16 ,  C07D498/04 ,  Y02A50/401

Abstract: Provided herein are compounds that bind to androgen receptors and/or modulate activity of androgen receptors. Also provided are methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions.

Abstract translation: 本文提供了结合雄激素受体和/或调节雄激素受体活性的化合物。 还提供了制备和使用这些化合物的方法。 还提供了包括这些化合物的组合物和用于制备和使用这些组合物的方法。

公开(公告)号：US12208071B2

公开(公告)日：2025-01-28

申请号：US16969521

申请日：2019-02-13

Applicant: LIGAND PHARMACEUTICALS INCORPORATED

Inventor： Lin Zhi ,  Ian Henderson ,  Joseph Kaloko ,  Martin Osterhout

IPC: A61K31/185 ,  A61K31/155 ,  A61K31/366 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/455 ,  A61K31/64 ,  A61K31/702 ,  A61K31/7032 ,  A61K38/28 ,  A61K38/31 ,  A61K45/06 ,  C07C67/00 ,  C07C67/343 ,  C07C201/12 ,  C07C209/36 ,  C07C231/02 ,  C07C231/12 ,  C07C309/24 ,  C07C315/04 ,  C07C315/06

Abstract: Provided herein are solid state forms of compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions and methods of treating, preventing, ameliorating, delaying the time to onset or reducing the risk for the development or progression of at least one condition, disease, or disorder for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance, hyperglycemia, ketoacidosis, or ketosis.